Hypertriglyceridemia

Nutrients

Volumn 5, Issue 3, 2013, Pages 981-1001

  Brahm, Amanda ^a   Hegele, Robert A ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALIPOGENE TIPARVOVEC; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DNA POLYMORPHISM; DOSE RESPONSE; DRUG EFFICACY; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HYPERLIPOPROTEINEMIA; HYPERLIPOPROTEINEMIA TYPE 1; HYPERLIPOPROTEINEMIA TYPE 2B; HYPERLIPOPROTEINEMIA TYPE 3; HYPERLIPOPROTEINEMIA TYPE 4; HYPERLIPOPROTEINEMIA TYPE 5; HYPERTRIGLYCERIDEMIA; LIFESTYLE MODIFICATION; MOLECULAR PATHOLOGY; MONOTHERAPY; NONHUMAN; PANCREATITIS; PATHOPHYSIOLOGY; PHARMACEUTICAL CARE; RISK REDUCTION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VIRAL GENE THERAPY;

EID: 84875444149     PISSN: 20726643     EISSN: None     Source Type: Journal    
DOI: 10.3390/nu5030981     Document Type: Article

References (73)

1. Yuan, G.; Al-Shali, K.Z.; Hegele, R.A. Hypertriglyceridemia: Its etiology, effects and treatment. Can. Med. Assoc. J. 2007, 176, 1113-1120.
2. Hegele, R.A. Plasma lipoproteins: Genetic influences and clinical implications. Nat. Rev. Genet. 2009, 10, 109-121.
3. Johansen, C.T.; Kathiresan, S.; Hegele, R.A. Genetic determinants of plasma triglycerides. J. Lipid Res. 2011, 52, 189-206.
4. Johansen, C.T.; Hegele, R.A. Genetic bases of hypertriglyceridemic phenotypes. Curr. Opin. Lipidol. 2011, 22, 247-253.
5. Johansen, C.T.; Hegele, R.A. The complex genetic basis of plasma triglycerides. Curr. Atheroscler. Rep. 2012, 14, 227-234.
6. Johansen, C.T.; Hegele, R.A. Allelic and phenotypic spectrum of plasma triglycerides. Biochim. Biophys. Acta 2012, 1821, 833-842.
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285, 2486-2497.
8. Berglund, L.; Brunzell, J.D.; Goldberg, A.C.; Goldberg, I.J.; Sacks, F.; Murad, H.M.; Stalenhoef, A.F.H. Evaluation and treatment of hypertriglyceridemia: An endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2012, 97, 2969-2989.
9. Hegele, R.A.; Ban, M.R.; Hsueh, N.; Kennedy, B.A.; Cao, H.; Zou, G.Y.; Anand, S.; Yusuf, S.; Huff, M.W.; Wang, J. A polygenic basis for four classical Frederickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia. Hum. Mol. Genet. 2009, 18, 4189-4194.
10. Feoli-Fonseca, J.C.; Lévy, E.; Godard, M.; Lambert, M. Familial lipoprotein lipase deficiency in infancy: Clinical, biochemical, and molecular study. J. Pediatr. 1998, 133, 417-423.
11. Rahalkar, A.R.; Hegele, R.A. Monogenic pediatric dyslipidemias: Classification, genetics and clinical spectrum. Mol. Genet. Metab. 2008, 93, 282-294.
12. Hall, L.D.; Ferringer, T. The best diagnosis is: Eruptive xanthoma. Cutis 2012, 90, 15-16.
13. Gotoda, T.; Shirai, K.; Ohta, T.; Kobayashi, J.; Yokoyama, S.; Oikawa, S.; Bujo, H.; Ishibashi, S.; Arai, H.; Yamashita, S. et al. Research committee for primary hyperlipidemia, research on measures against intractable diseases by the ministry of health, labour and welfare in Japan. Diagnosis and management of type I and type V hyperlipoproteinemia. J. Atheroscler. Thromb. 2012, 19, 1-12.
14. Kawashiri, M.A.; Higashikata, T.; Mizuno, M.; Takata, M.; Katsuda, S.; Miwa, K.; Nozue, T.; Nohara, A.; Inazu, A.; Kobayashi, J. et al. Long-term course of lipoprotein lipase (LPL) deficiency due to homozygous LPL (Arita) in a patient with recurrent pancreatitis, retained glucose tolerance, and atherosclerosis. J. Clin. Endocrinol. Metab. 2005, 90, 6541-6544.
15. Sandhu, S.; Al-Sarraf, A.; Taraboanta, C.; Frohlich, J.; Francis, G.A. Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: A retrospective cohort study. Lipids Health Dis. 2011, 10, 157.
16. Khokhar, A.S.; Seidner, D.L. The pathophysiology of pancreatitis. Nutr. Clin. Pract. 2004, 19, 5-15.
17. Goldberg, I.J.; Eckel, R.H.; McPherson, R. Triglycerides and heart disease: Still a hypothesis? Arterioscler. Thromb. Vasc. Biol. 2011, 31, 1716-1725.
18. Benlian, P.; de Gennes, J.L.; Foubert, L.; Zhang, H.; Gagné, S.E.; Hayden, M. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N. Engl. J. Med. 1996, 335, 848-854.
19. Beil, U.; Grundy, S.M.; Crouse, J.R.; Zech, L. Triglyceride and cholesterol metabolism in primary hypertriglyceridemia. Arteriosclerosis 1982, 2, 44-57.
20. Rahalkar, A.R.; Giffen, F.; Har, B.; Ho, J.; Morrison, K.M.; Hill, J.; Wang, J.; Hegele, R.A.; Joy, T. Novel LPL mutations associated with lipoprotein lipase deficiency: Two case reports and a literature review. Can. J. Physiol. Pharmacol. 2009, 87, 151-160.
21. Connelly, P.W.; Maguire, G.F.; Hofmann, T.; Little, J.A. Structure of apolipoprotein C-IIToronto, a nonfunctional human apolipoprotein. Proc. Natl. Acad. Sci. USA 1987, 84, 270-273.
22. Calandra, S.; Priore Oliva, C.; Tarugi, P.; Bertolini, S. APOA5 and triglyceride metabolism, lesson from human APOA5 deficiency. Curr. Opin. Lipidol. 2006, 17, 122-127.
23. Young, S.G.; Davies, B.S.; Voss, C.V.; Gin, P.; Weinstein, M.M.; Tontonoz, P.; Reue, K.; Bensadoun, A.; Fong, L.G.; Beigneux, A.P. GPIHBP1, an endothelial cell transporter for lipoprotein lipase. J. Lipid Res. 2011, 52, 1869-1884.
24. Péterfy, M. Lipase maturation factor 1: A lipase chaperone involved in lipid metabolism. Biochim. Biophys. Acta 2012, 1821, 790-794.
25. Teslovich, T.M.; Musunuru, K.; Smith, A.V.; Edmondson, A.C.; Stylianou, I.M.; Koseki, M.; Pirruccello, J.P.; Ripatti, S.; Chasman, D.I.; Willer, C.J. et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010, 466, 707-713.
26. Johansen, C.T.; Wang, J.; Lanktree, M.B.; McIntyre, A.D.; Ban, M.R.; Martins, R.A.; Kennedy, B.A.; Hassell, R.G.; Visser, M.E.; Schwartz, S.M. et al. An increased burden of common and rare lipid-associated risk alleles contributes to the phenotypic spectrum of hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 1916-1926.
27. Johansen, C.T.; Wang, J.; Lanktree, M.B.; Cao, H.; McIntyre, A.D.; Ban, M.R.; Martins, R.A.; Kennedy, B.A.; Hassell, R.G.; Visser M.E. et al. Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat. Genet. 2010, 42, 684-687.
28. Johansen, C.T.; Wang, J.; McIntyre, A.D.; Martins, R.A.; Ban, M.R.; Lanktree, M.B.; Huff, M.W.; Péterfy, M.; Mehrabian, M.; Lusis, A.J. et al. Excess of rare variants in non-genome-wide association study candidate genes in patients with hypertriglyceridemia. Circ. Cardiovasc. Genet. 2012, 5, 66-72.
29. Ewald, N.; Kloer, H.U. Severe hypertriglyceridemia: An indication for apheresis? Atheroscler. Suppl. 2009, 10, 49-52.
30. Gaudet, D.; de Wal, J.; Tremblay, K.; Déry, S.; van Deventer, S.; Freidig, A.; Brisson, D.; Méthot, J. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler. Suppl. 2010, 11, 55-60.
31. Stroes, E.S.; Nierman, M.C.; Meulenberg, J.J.; Franssen, R.; Twisk, J.; Henny, C.P.; Maas, M.M.; Zwinderman, A.H.; Ross, C.; Aronica, E. et al. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 2303-2304.
32. Evans, D.; Aberle, J.; Beil, F.U. The relative importance of common and rare genetic variants in the development of hypertriglyceridemia. Expert Rev. Cardiovasc. Ther. 2011, 9, 637-644.
33. Mahley, R.W.; Huang, Y.; Rall, S.C. Jr. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia) questions, quandaries, and paradoxes. J. Lipid Res. 1999, 40, 1933-1949.
34. Tullu, M.S.; Advirkar, A.V.; Ghildiyal, R.G.; Tambe, S. Familial hypertriglyceridemia. Indian J. Pediatr. 2008, 75, 1257-1258.
35. Brunzell, J.D.; Deeb, S.S. Familial Lipoprotein Deficiency, Apo C-II Deficiency, and Hepatic Lipase Deficiency. In Metabolic and Molecular Bases of Inherited Disease, 8th ed.; Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D., Eds.; McGraw-Hill: New York, NY, USA, 2001; pp. 2789-2816.
36. Davignon, J.; Dufour, R. Primary Hyperlipidemias: An Atlas of Investigation and Diagnosis; Clinical Publishing: Oxford, UK, 2007.
37. Brouwers, M.C.; van Greevenbroek, M.M.; Stehouwer, C.D.; de Graaf, J.; Stalenhoef, A.F. The genetics of familial combined hyperlipidaemia. Nat. Rev. Endocrinol. 2012, 8, 352-362.
38. Press, M.; Hartop, P.J.; Prottey, C. Correction of essential fatty-acid deficiency in man by the cutaneous application of sunflower-seed oil. Lancet 1974, 303, 597-598.
39. Mahley, R.W.; Weisgraber, K.H.; Farese, R.V., Jr. Disorders of Lipid Metabolism. In Williams Textbook of Endocrinology, 10th ed.; Larsen, P.R., Kronenberg, H.M., Melmed, S., Polonsky, K.S., Eds.; Elsevier Science: Philadelphia, PA, USA, 2003; pp. 1642-1705.
40. Staels, B.; Dallongeville, J.; Auwerx, J.; Schoonjans, K.; Leitersdorf, E.; Fruchart, J.C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998, 98, 2088-2093.
41. Leaf, D.A.; Connor, W.E.; Illingworth, D.R.; Bacon, S.P.; Sexton, G. The hypolipidemic effects of gemfibrozil in type V hyperlipidemia. A double-blind, crossover study. JAMA 1989, 262, 3154-3160.
42. Goldberg, A.C.; Schonfeld, G.; Feldman, E.B.; Ginsberg, H.N.; Hunninghake, D.B.; Insull, W., Jr.; Knopp, R.H.; Kwiterovich, P.O.; Mellies, M.J.; Pickering, J. Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: A double-blind, placebo-controlled multicenter US study. Clin. Ther. 1989, 11, 69-83.
43. Lussier-Cacan, S.; Bard, J.M.; Boulet, L.; Nestruck, A.C.; Grothé, A.M.; Fruchart, J.C.; Davignon, J. Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III. Atherosclerosis 1989, 78, 167-182.
44. Baggio, G.; Gasparotto, A.; Ciuffetti, G.; Valerio, G.; Fellin, R.; Senin, U.; Gabelli, C.; Crepaldi, G. Long-term effect of fenofibrate on lipoprotein level and composition in different types of genetic hyperlipidemias. Pharmacol. Res. Commun. 1986, 18, 471-480.
45. Civeira, F.; Cenarro, A.; Ferrando, J.; Puzo, J.; Garcia-Ot n, A.L.; Mozas, P.; Pocov, M. Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia. Am. Heart J. 1999, 138, 156-162.
46. Keech, A.; Simes, R.J.; Barter, P.; Best, J.; Scott, R.; Taskinen, M.R.; Forder, P.; Pillai, A.; Davis, T.; Glasziou, P.; et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 2005, 366, 1849-1861.
47. Vakkilainen, J.; Steiner, G.; Ansquer, J.C.; Aubin, F.; Rattier, S.; Foucher, C.; Hamsten, A.; Taskinen, M.R.; DAIS Group. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: The diabetes atherosclerosis intervention study (DAIS). Circulation 2003, 107, 1733-1737.
48. Knopp, R.H.; Brown, W.V.; Dujovne, C.A.; Farquhar, J.W.; Feldman, E.B.; Goldberg, A.C.; Grundy, S.M.; Lasser, N.L.; Mellies, M.J.; Palmer, R.H. Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia. Am. J. Med. 1987, 83, 50-59.
49. Frick, M.H.; Elo, O.; Haapa, K.; Heinonen, O.P.; Heinsalmi, P.; Helo, P.; Huttunen, J.K.; Kaitaniemi, P.; Koskinen, P.; Manninen, V. Helsinki heart study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 1987, 317, 1237-1245.
50. Rubins, H.B.; Robins, S.J.; Collins, D.; Fye, C.L.; Anderson, J.W.; Elam, M.B.; Faas, F.H.; Linares, E.; Schaefer, E.J.; Schectman, G. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high-density lipoprotein cholesterol intervention trial study group. N. Engl. J. Med. 1999, 341, 410-418.
51. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The bezafibrate infarction prevention (BIP) study. Circulation 2000, 102, 21-27.
52. ACCORD Study Group; Ginsberg, H.N.; Elam, M.B.; Lovato, L.C.; Crouse, J.R., III; Leiter, L.A.; Linz, P.; Friedewald, W.T.; Buse, J.B.; Gerstein, H.C. et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 2010, 362, 1563-1574.
53. Abourbih, S.; Filion, K.B.; Joseph, L.; Schiffrin, E.L.; Rinfret, S.; Poirier, P.; Pilote, L.; Genest, J.; Eisenberg, M.J. Effect of fibrates on lipid profiles and cardiovascular outcomes: A systematic review. Am. J. Med. 2009, 122, e1-e8.
54. Goldberg, A.; Alagona, P., Jr.; Capuzzi, D.M.; Guyton, J.; Morgan, J.M.; Rodgers, J.; Sachson, R.; Samuel, P. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am. J. Cardiol. 2000, 85, 1100-1105.
55. Taylor, A.J.; Lee, H.J.; Sullenberger, L.E. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr. Med. Res. Opin. 2006, 22, 2243-2250.
56. Taylor, A.J.; Sullenberger, L.E.; Lee, H.J.; Grace, K.A. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004, 110, 3512-3517.
57. Blankenhorn, D.H.; Nessim, S.A.; Johnson, R.L.; Sanmarco, M.E.; Azen, S.P.; Cashin-Hemphill, L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987, 257, 3233-3240.
58. Kane, J.P.; Malloy, M.J.; Ports, T.A.; Phillips, N.R.; Diehl, J.C.; Havel, R.J. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990, 264, 3007-3012.
59. Brown, B.G.; Zhao, X.Q.; Chait, A.; Fisher, L.D.; Cheung, M.C.; Morse, J.S.; Dowdy, A.A.; Marino, E.K.; Bolson, E.L.; Alaupovic, P.;et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 2001, 345, 1583-1592.
60. Brown, G.; Albers, J.J.; Fisher, L.D.; Schaefer, S.M.; Lin, J.T.; Kaplan, C.; Zhao, X.Q.; Bisson, B.D.; Fitzpatrick, V.F.; Dodge, H.T. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med. 1990, 323, 1289-1298.
61. Boden, W.E.; AIM-HIGH Investigators; Probstfield, J.L.; Anderson, T.; Chaitman, B.R.; Desvignes-Nickens, P.; Koprowicz, K.; McBride, R.; Teo, K.; Weintraub, W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 2011, 365, 2255-2267.
62. Bocan, T.M. Pleiotropic effects of HMG-CoA reductase inhibitors. Curr. Opin. Investig. Drugs 2002, 3, 1312-1317.
63. Knopp, R.H. Drug treatment of lipid disorders. N. Engl. J. Med. 1999, 341, 498-511.
64. Saito, Y.; Yamada, N.; Shirai, K.; Sasaki, J.; Ebihara, Y.; Yanase, T.; Fox, J.C. Effect of rosuvastatin 5-20 mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia. Atherosclerosis 2007, 194, 505-511.
65. Feussner, G.; Eichinger, M.; Ziegler, R. The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia. Clin. Investig. 1992, 70, 1027-1035.
66. Illingworth, D.R.; O'Malley, J.P. The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia. Metabolism 1990, 39, 403-409.
67. Jones, P.H.; Davidson, M.H. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am. J. Cardiol. 2005, 95, 120-122.
68. McKenney, J.M.; Farnier, M.; Lo, K.W; Bays, H.E.; Perevozkaya, I.; Carlson, G.; Davies, M.J.; Mitchel, Y.B.; Gumbiner, B. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J. Am. Coll. Cardiol. 2006, 47, 1584-1587.
69. Davidson, M.H. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am. J. Cardiol. 2006, 98, 27i-33i.
70. Skulas-Ray, A.C.; West, S.G.; Davidson, M.H.; Kris-Etherton, P.M. Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia. Expert Opin. Pharmacother. 2008, 9, 1237-1248.
71. Dallongeville, J.; Boulet, L.; Davignon, J.; Lussier-Cacan, S. Fish oil supplementation reduces beta-very low density lipoprotein in type III dysbetalipoproteinemia. Arterioscler. Thromb. 1991, 11, 864-871.
72. Dietary supplementation with N-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Gruppo Italiano per lo studio della sopravvivenza nell'Infarto miocardico. Lancet 1999, 354, 447-455.
73. Yokoyama, M.; Origasa, H.; Matsuzaki, M.; Matsuzawa, Y.; Saito, Y.; Ishikawa, Y.; Oikawa, S.; Sasaki, J.; Hishida, H.; Itakura, H. et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet 2007, 369, 1090-1098.